

Amendments to the Specification

Please replace the paragraph at page 22, lines 17 through 27 with the following amended paragraph:

The present invention discloses the use of whole glucan particles with antibodies from essentially any source, including antibodies generated naturally in response to infection, antibodies generated in response to administration of a vaccine, and monoclonal antibodies directly administered as part of a therapy including the use of β -glucan. The majority of humanized mAbs containing the human IgG1 Fc-region have been shown to activate complement, such as Herceptin™ HERCEPTIN® (trastuzumab), Rituxan™ RITUXAN® (rituximab), and Erbix™ ERBITUX® (cetuximab) (Spiridon, C. I., *et al.*, *Clin. Cancer Res.*, 8: 1720-1730 (2002), Idusogie, E. E., *et al.*, *J. Immunol.*, 164: 4178-4184 (2000), Cragg, M. S., *et al.*, *Blood*, 101: 1045-1052 (2003), Herbst, R. S. and Hong, W. K., *Semin. Oncol.*, 29: 18-30 (2002). In certain embodiments the whole glucan particles and antibodies work synergistically.

Please replace the paragraph starting on page 22, line 28 through page 23, line 6 with the following amended paragraph:

As illustrative of the inventive concept, β -glucans such as whole glucan particles could be administered to act synergistically with Herceptin™ HERCEPTIN®, a monoclonal antibody sold by Genentech for use in immunotherapy of breast cancer. Herceptin™ HERCEPTIN® is a mAb that recognizes the her2 cell surface antigen which is present on 20% of breast cancer cell types. Clinical trials have demonstrated that Herceptin™ HERCEPTIN® is saving lives, but its effectiveness could be significantly enhanced through concurrent administration of β -glucan. NSG therapy along with Herceptin™ HERCEPTIN® therapy could result in a significant increase in the proportion of women responding to Herceptin™ HERCEPTIN® therapy with long lasting remission of their breast cancer. Currently, only 15% of women receiving Herceptin™ HERCEPTIN® therapy show long lasting remission.

Please replace the paragraph at page 23, lines 7 through 19 with the following amended paragraph:

Another mAb whose activity is enhanced by whole glucan particles is rituximab, a monoclonal antibody used to treat a type of non-Hodkin's lymphoma (NHL), a cancer of the immune system. ~~Rituxan~~TM RITUXAN®, (Rituximab) is effective for patients with low-grade B-cell NHL who have not responded to standard treatments. It targets and destroys white blood cells (B-cells) that have been transformed, resulting in cancerous growth. Rituximab is a genetically engineered version of a mouse antibody that contains both human and mouse components. In the main clinical study of 166 patients with advanced low-grade or slow-growing NHL, which represents about 50% of the 240,000 NHL patients in the United States, tumors shrunk by at least one half in 48% of the patients who completed treatment with rituximab, with 6% having complete remission. Beta-glucan can be expected to significantly increase the effectiveness of this treatment, by enhancing the destruction of antibody-marked tumor cells.